These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20815225)

  • 1. [Thought on several problems of clinical revaluation of post-marketing herb research].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(12):1641-3. PubMed ID: 20815225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
    Shang HC; Zhang BL; Li YP
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
    Xie YM; Wang X; Wang N; Chang YP
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discussion on methods of sample size estimation in conducting clinical reevaluation of postmarketing Chinese medicine].
    Tian F; Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Apr; 36(8):1097-102. PubMed ID: 21809593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thought on several problems of post-marketing herbs clinical evaluation in special populations].
    Zhou A; Lian F
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing clinical study of traditional Chinese medicine--lessons learned from comprehensive evaluation of Fufang Zaoren capsule].
    Qing S; Gao L; Zhang L; Jia JP; Liu XM; Ji SL; Yang XH
    Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(21):3790-4. PubMed ID: 24494575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
    Kou Q; Zhao S; Feng G; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk control system construction of Shenfu injection].
    Tian DL; Li K; Jiang JJ; Zhu YN
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2814-7. PubMed ID: 23285942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
    Li X; Tang J; Meng F; Li C; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
    Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research on foreign countries laws and regulations on surveillance and reporting of postmarketing drugs adverse reactions].
    Tian F; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(11):1464-7. PubMed ID: 19771884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Literature review of post-marketing clinical evaluation of Xiaoke pill].
    Liu H; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2851-4. PubMed ID: 22292383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Survey on Xiaoke pill treating diabetes mellitus in small cities' Chinese medicine hospital for post-marketing surveillance].
    Xie Y; Zhao Y; Liu H; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2859-61. PubMed ID: 22292385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].
    Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2904-6. PubMed ID: 22292397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
    Li X; Tang J; Meng F; Li C; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].
    Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC
    Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.